{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:27:57Z","timestamp":1787185677833,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jcjo.2026.03.007","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T03:48:13Z","timestamp":1775620093000},"page":"1018-1024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A real-world pharmacovigilance analysis of uveitis from systemic medications"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1025-4765","authenticated-orcid":false,"given":"Fahad","family":"Butt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2692-0759","authenticated-orcid":false,"given":"Andrew","family":"Mihalache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4044-3215","authenticated-orcid":false,"given":"Salem Abu","family":"Al-Burak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3404-5376","authenticated-orcid":false,"given":"Ryan S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-5968","authenticated-orcid":false,"given":"Marko M.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev H.","family":"Muni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2026.03.007_bib0001","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1750-1172-7-57","article-title":"Uveitis- a rare disease often associated with systemic diseases and infections\u2014a systematic review of 2619 patients","volume":"7","author":"Barisani-Asenbauer","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0002","series-title":"StatPearls","article-title":"Uveitis","author":"Duplechain","year":"2025"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.968345","article-title":"Beh\u00e7et uveitis: Current practice and future perspectives","volume":"9","author":"Aboul Naga","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2022-001091","article-title":"Systematic review of clinical practice guidelines for uveitis","volume":"8","author":"Ghadiri","year":"2023","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0005","doi-asserted-by":"crossref","DOI":"10.5935\/0004-2749.20220040","article-title":"Moraes Jr HVD. Causes and characteristics of uveitis cases at a reference university hospital in Rio de Janeiro, Brazil","volume":"85","author":"Moraes","year":"2022","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0006","article-title":"Unilateral posterior uveitis in a patient receiving nivolumab for malignant melanoma","volume":"15","author":"Giannakis","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0007","first-page":"83","article-title":"Drug-induced ocular inflammation","volume":"133","author":"Samalia","year":"2020","journal-title":"N Z Med J"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0008","first-page":"420","article-title":"A standardized dataset of a spontaneous adverse event reporting system","volume":"10","author":"Khaleel","year":"2022","journal-title":"Healthc Basel Switz"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0009","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/clpt.2014.17","article-title":"Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics","volume":"95","author":"Fang","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA\u2014Inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0011","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0012","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1038\/s41598-024-60493-w","article-title":"Phosphodiesterase type 5 inhibitors related hearing impairment: a real world study based on the FDA adverse event reporting system","volume":"14","author":"Zhang","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0013","doi-asserted-by":"crossref","first-page":"276","DOI":"10.18502\/jovr.v17i2.10804","article-title":"Review of systemic biologics and local immunosuppressive medications in uveitis","volume":"17","author":"S Mehta","year":"2022","journal-title":"J Ophthalmic Vis Res"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0014","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.3390\/v2122803","article-title":"Cidofovir activity against poxvirus infections","volume":"2","author":"Andrei","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0015","first-page":"1519","article-title":"Cidofovir use in acyclovir-resistant herpes infection","volume":"31","author":"Martinez","year":"1997","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0016","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00003495-199958020-00015","article-title":"Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS","volume":"58","author":"Plosker","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0017","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/eye.1999.89","article-title":"Ocular complications of intravenous cidofovir for cytomegalovirus retinitis in patients with AIDS","volume":"13","author":"Bainbridge","year":"1999","journal-title":"Eye"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0018","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1869-5760-3-43","article-title":"Drug-induced uveitis","volume":"3","author":"London","year":"2013","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0019","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0002-9394(00)00486-4","article-title":"Ocular side-effects from systemic HPMPC (Cidofovir) for a non\u2013ocular cytomegalovirus infection","volume":"130","author":"Scott","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0020","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1128\/AAC.04348-14","article-title":"Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients","volume":"59","author":"Caruso Brown","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0021","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1136\/bjo.83.10.1153","article-title":"Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis","volume":"83","author":"Ambati","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0022","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0161-6420(97)30278-4","article-title":"Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis","volume":"104","author":"Chavez-de","year":"1997","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0023","series-title":"StatPearls","article-title":"Foscarnet","author":"Garikapati","year":"2025"},{"issue":"Suppl 1","key":"10.1016\/j.jcjo.2026.03.007_bib0024","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/clinids\/22.Supplement_1.S3","article-title":"Antimicrobial activity of rifabutin","volume":"22","author":"Kunin","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0025","doi-asserted-by":"crossref","first-page":"525","DOI":"10.5935\/0004-2749.202100118","article-title":"Rifabutin-induced severe panuveitis: an unusual case of early onset in a patient with AIDS","volume":"84","author":"Biancardi","year":"2021","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0026","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1177\/106002809502901114","article-title":"Rifabutin-associated uveitis","volume":"29","author":"Tseng","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0027","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.tjo.2014.08.004","article-title":"Bilateral uveitis associated with concurrent administration of rifabutin and nelfinavir","volume":"5","author":"Cheng","year":"2015","journal-title":"Taiwan J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0028","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1086\/517366","article-title":"Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis","volume":"177","author":"Shafran","year":"1998","journal-title":"J Infect Dis"},{"issue":"Supplement_1","key":"10.1016\/j.jcjo.2026.03.007_bib0029","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1093\/clinids\/22.Supplement_1.S43","article-title":"Mycobacterium avium complex infection, rifabutin, and uveitis\u2014Is there a connection?","volume":"22","author":"Nichols","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamaophthalmol.2014.3598","article-title":"Risk for uveitis with oral moxifloxacin: a comparative safety study","volume":"133","author":"Eadie","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0031","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jamaophthalmol.2015.4092","article-title":"Oral fluoroquinolones and the risk of uveitis","volume":"134","author":"Sandhu","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0032","series-title":"StatPearls","article-title":"Infliximab","author":"Fatima","year":"2025"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0033","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/ecco-jcc\/jjv030","article-title":"Infliximab-induced anterior uveitis in a patient with ulcerative colitis","volume":"9","author":"Singla","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.740057","article-title":"TNF-\u03b1 in uveitis: from bench to clinic","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0035","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4103\/tjo.tjo_88_17","article-title":"Bilateral anterior uveitis after immunotherapy for malignant melanoma","volume":"8","author":"Chang","year":"2018","journal-title":"Taiwan J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0036","series-title":"StatPearls","article-title":"Ipilimumab","author":"Saad","year":"2025"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0037","first-page":"1551","article-title":"Current development status of MEK inhibitors","volume":"22","author":"Cheng","year":"2017","journal-title":"Mol Basel Switz"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0038","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejca.2020.11.027","article-title":"The association between immune checkpoint or BRAF\/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma","volume":"144","author":"Dimitriou","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0039","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1093\/oncolo\/oyae014","article-title":"Ocular effects of MEK inhibitor therapy: literature review, clinical presentation, and best practices for mitigation","volume":"29","author":"Jeng-Miller","year":"2024","journal-title":"The Oncologist"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0040","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000446845","article-title":"Risk of ophthalmic adverse effects in patients treated with mek inhibitors: a systematic review and meta-analysis","volume":"57","author":"Alves","year":"2017","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0041","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/IIO.0000000000000434","article-title":"Cancer immunotherapy and uveitis: balancing anti-tumor immunity and ocular autoimmunity","volume":"62","author":"Rali","year":"2022","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0042","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40265-020-01314-y","article-title":"Uveitis therapy: the corticosteroid options","volume":"80","author":"Valdes","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0043","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3390\/cancers12071823","article-title":"BRAF inhibitors: molecular targeting and immunomodulatory actions","volume":"12","author":"Proietti","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0044","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ajo.2024.07.002","article-title":"Real-world incidence of incident noninfectious uveitis in patients treated with BRAF inhibitors: a nationwide clinical cohort study","volume":"267","author":"Jung","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0045","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1177\/11206721221132872","article-title":"Ophthalmic adverse effects of BRAF inhibitors","volume":"33","author":"Castillejo Becerra","year":"2023","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0046","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0047","doi-asserted-by":"crossref","first-page":"E431","DOI":"10.1503\/cmaj.111752","article-title":"Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study","volume":"184","author":"Etminan","year":"2012","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0048","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s40264-023-01345-w","article-title":"Challenges and opportunities in accessing and analysing faers data: a call towards a collaborative approach","volume":"46","author":"Giunchi","year":"2023","journal-title":"Drug Saf"},{"key":"10.1016\/j.jcjo.2026.03.007_bib0049","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12886-020-01519-5","article-title":"Vogt\u2013Koyanagi\u2013Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report","volume":"20","author":"Kikuchi","year":"2020","journal-title":"BMC Ophthalmol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000841822600089X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000841822600089X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:21:06Z","timestamp":1787185266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000841822600089X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S000841822600089X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.03.007","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A real-world pharmacovigilance analysis of uveitis from systemic medications","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Canadian Ophthalmological Society.","name":"copyright","label":"Copyright"}]}}